×
About 282,580 results
Safety and Side Effects of Rifampin versus Isoniazid in Children.
https://doi.org/10.1056/NEJMoa1714284
The New England Journal of Medicine; Diallo T, Adjobimey M et. al.

Aug 1st, 2018 - The treatment of latent infection with Mycobacterium tuberculosis is important in children because of their vulnerability to life-threatening forms of tuberculosis disease. The current standard treatment - 9 months of isoniazid - has been associated with poor adherence and toxic effects, which have hampered the effectiveness of the drug. In adults, treatment with 4 months of rifampin has been s...

Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty.
https://doi.org/10.1056/NEJMoa1712746
The New England Journal of Medicine; Anderson DR, Dunbar M et. al.

Feb 21st, 2018 - Clinical trials and meta-analyses have suggested that aspirin may be effective for the prevention of venous thromboembolism (proximal deep-vein thrombosis or pulmonary embolism) after total hip or total knee arthroplasty, but comparisons with direct oral anticoagulants are lacking for prophylaxis beyond hospital discharge. We performed a multicenter, double-blind, randomized, controlled trial i...

Effect of Oral Prednisolone on Symptom Duration and Severity in Nonasthmatic Adults Wit...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5817483
JAMA Hay AD, Little P et. al.

Aug 22nd, 2017 - Acute lower respiratory tract infection is common and often treated inappropriately in primary care with antibiotics. Corticosteroids are increasingly used but without sufficient evidence. To assess the effects of oral corticosteroids for acute lower respiratory tract infection in adults without asthma. Multicenter, placebo-controlled, randomized trial (July 2013 to final follow-up October 2014...

Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis
https://www.nejm.org/doi/full/10.1056/NEJMoa1909953
The New England Journal of Medicine; Tait, D. et. al.

Oct 28th, 2019 - BACKGROUND Results of an earlier analysis of a trial of the M72/AS01E candidate vaccine against Mycobacterium tuberculosis showed that in infected adults, the vaccine provided 54.0% protection against active pulmonary tuberculosis disease, without evident safety concerns. We now report the results of the 3-year final analysis of efficacy, safety, and immunogenicity. METHODS From August 201...

Melinta Therapeutics Announces U.S. FDA Approval of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)
http://ir.melinta.com/news-releases/news-release-details/melinta-therapeutics-announces-us-fda-approval-supplemental-new

Oct 23rd, 2019 - Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced the U.S. Food and Drug Administration (FDA) has approved BAXDELA® (delafloxacin) for the treatment of adult patients with community-acquired bacterial pneumonia (CABP) caused by designated susceptible b...

Metoprolol for the Prevention of Acute Exacerbations of COPD
https://www.nejm.org/doi/full/10.1056/NEJMoa1908142
The New England Journal of Medicine; Dransfield, M. et. al.

Oct 19th, 2019 - Observational studies suggest that beta-blockers may reduce the risk of exacerbations and death in patients with moderate or severe chronic obstructive pulmonary disease (COPD), but these findings have not been confirmed in randomized trials.

Genentech Announces FDA Approval of Xofluza (Baloxavir Marboxil) for People at High Risk of Developing Influenza-Related Complications
https://www.gene.com/media/press-releases/14817/2019-10-17/genentech-announces-fda-approval-of-xofl

Oct 16th, 2019 - Single-dose Xofluza is the first and only antiviral medicine indicated specifically for patients at high risk of developing serious complications from influenza (flu) The Centers for Disease Control and Prevention (CDC) defines people at high risk of serious flu complications as those who have conditions such as asthma, chronic lung disease, diabetes, heart disease, morbid obesity or adults ...

Predicting the Risk of Postoperative Pulmonary Complications
https://www.aafp.org/afp/2019/1015/p499.html
American Family Physician;

Oct 14th, 2019 - The incidence of pulmonary complications following major surgery is estimated to be 1% to 23%, with the risk varying based on patient factors and the type of surgery.1 Postoperative pulmonary complications include pneumonia, tracheobronchitis, pulmonary edema, pulmonary embolism, atelectasis, pleural effusion, pneumothorax, bronchospasm, aspiration, respiratory failure, and acute respiratory di...

Anticoagulation: Updated Guidelines for Outpatient Management
https://www.aafp.org/afp/2019/1001/p426.html
American Family Physician;

Sep 30th, 2019 - Anticoagulation therapy is recommended for preventing, treating, and reducing the recurrence of venous thromboembolism, and preventing stroke in persons with atrial fibrillation. Direct oral anticoagulants are first-line agents for eligible patients for treating venous thromboembolism and preventing stroke in those with nonvalvular atrial fibrillation. Vitamin K antagonists are recommended for ...

Global Initiative for Asthma: Global Strategy for Asthma Management & Prevention
https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf

Sep 29th, 2019 - The 2019 update of the Global Strategy for Asthma Management and Prevention incorporates new scientific information about asthma based on a review of recent scientific literature by an international panel of experts on the GINA Science Committee. This comprehensive and practical resource about one of the most common chronic lung diseases worldwide contains extensive citations from the scientifi...

Can Mild Asthma Be Managed with Only As-Needed Inhaled Steroids Plus a Bronchodilator?
https://www.jwatch.org/na49830/2019/09/26/can-mild-asthma-be-managed-with-only-needed-inhaled

Sep 25th, 2019 - David J. Amrol, MD reviewing Hardy J et al. Lancet 2019 Sep 14 Gauthier M and Wenzel SE. Lancet 2019 Sep 14

Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine: a population-based cohort study
http://www.cmaj.ca/content/191/37/E1018
CMAJ

Sep 15th, 2019 - BACKGROUND: Donepezil, rivastigmine and galantamine are popular cholinesterase inhibitors used to manage the symptoms of Alzheimer disease and other dementias; regulatory agencies in several countries warn about a possible risk of rhabdomyolysis with donepezil, based on information from case reports. Our goal was to investigate the 30-day risk of admission to hospital with rhabdomyolysis associ...

Nucala is the first biologic approved in the US for six to 11-year-old children with severe eosinophilic asthma
https://www.gsk.com/en-gb/media/press-releases/nucala-is-the-first-biologic-approved-in-the-us-for-six-to-11-year-old-children-with-severe-eosinophilic-asthma/

Sep 11th, 2019 - GlaxoSmithKline (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab) for use in children as young as six years old who are living with severe eosinophilic asthma. Nucala is the only targeted biologic to be approved for the condition in the six to 11-year age group in the US.

GE Healthcare Receives FDA Clearance of First Artificial Intelligence Algorithms Embedded On-Device to Prioritize Critical Chest X-ray Review
https://www.genewsroom.com/press-releases/ge-healthcare-receives-fda-clearance-first-artificial-intelligence-algorithms

Sep 11th, 2019 - GE Healthcare today announced the Food and Drug Administration’s 510(k) clearance of Critical Care Suite, an industry-first collection of artificial intelligence (AI) algorithms embedded on a mobile X-ray device. Built in collaboration with UC San Francisco (UCSF), using GE Healthcare’s Edison platform, the AI algorithms help to reduce the turn-around time it can take for radiologists to review...

Menopausal Estrogen-Alone Therapy and Health Outcomes in Women With and Without Bilateral Oophorectomy: A Randomized Trial
https://annals.org/aim/article-abstract/2749725/menopausal-estrogen-alone-therapy-health-outcomes-women-without-bilateral-oophorectomy
Annals of Internal Medicine;

Sep 9th, 2019 - Background: Whether health outcomes of menopausal estrogen therapy differ between women with and without bilateral salpingo-oophorectomy (BSO) is unknown. Objective: To examine estrogen therapy outcomes by BSO status, with additional stratification by 10-year age groups. Design: Subgroup analyses of the randomized Women's Health Initiative Estrogen-Alone Trial. (ClinicalTrials.gov: NCT...

New European Society of Cardiology Guidelines Address Dyslipidemias, SVT, CCS, Acute Pulmonary Embolism and Diabetes
https://www.acc.org/latest-in-cardiology/articles/2019/08/31/06/50/new-esc-guidelines-address-dyslipidemias-esc-2019

Aug 29th, 2019 - The European Society of Cardiology (ESC) released five separate guidelines covering dyslipidemias, supraventricular tachycardia, chronic coronary syndrome, acute pulmonary embolism, and diabetes as part of ESC Congress 2019 and published in the European Heart Journal.

FDA approves new antibiotic to treat community-acquired bacterial pneumonia
https://www.fda.gov/news-events/press-announcements/fda-approves-new-antibiotic-treat-community-acquired-bacterial-pneumonia

Aug 18th, 2019 - The U.S. Food and Drug Administration today approved Xenleta (lefamulin) to treat adults with community-acquired bacterial pneumonia. “This new drug provides another option for the treatment of patients with community-acquired bacterial pneumonia, a serious disease,” said Ed Cox, M.D., M.P.H., director of FDA’s Office of Antimicrobial Products. “For managing this serious disease, it is impor...

FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs
https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-resistant-forms-tuberculosis-affects-lungs

Aug 13th, 2019 - The U.S. Food and Drug Administration today approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant tuberculosis (TB) of the lungs. “The threat of antimicrobial-resistant infections is a key challenge we face as a public health agency,” said FDA Principal Deputy Commissioner Amy Abernethy, M.D., Ph.D. “The b...

Risk of Acute Myocardial Infarction and Ischemic Stroke in Patients with Asthma Exacerbation: A Population-Based, Self-Controlled Case Series Study
https://www.sciencedirect.com/science/article/abs/pii/S2213219819306178?via%3Dihub
The Journal of Allergy and Clinical Immunology: In Practice; Raita, Y. et. al.

Jul 15th, 2019 - Background Patients with asthma have a high incidence of acute myocardial infarction and ischemic stroke. Objective To investigate the acute effect of asthma exacerbation on these cardiovascular events. Methods Using population-based inpatient data of 3 geographically diverse US states (Florida, Nebraska, and New York) during the period 2011 to 2014, we conducted a self-controlled case...

Teva Announces FDA Approval of AirDuo® Digihaler™ (fluticasone propionate 113 mcg and salmeterol 14 mcg) Inhalation Powder
https://tevapharm.com/news/teva_announces_fda_approval_of_airduo_sup_reg_sup_digihaler_trade_fluticasone_propionate_113_mcg_and_salmeterol_14_mcg_inhalation_powder_07_19.aspx

Jul 14th, 2019 - Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has approved AirDuo® Digihaler™ (fluticasone propionate 113 mcg and salmeterol 14 mcg) Inhalation Powder, a combination therapy digital inhaler with built-in sensors that connects to a companion mobile application to provide information on inhaler use to people with asthma....